
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is well-positioned in the insulin pump market, particularly due to its differentiated product design and first-mover advantage in the Type 2 Diabetes (T2D) segment, which enhances its competitive edge. The company is demonstrating a commitment to improving gross margins, coupled with expectations of operating margin expansion of 100 basis points in both 2025 and 2026, indicating a focus on financial efficiency. Additionally, the operational adjustments in net interest expense further reflect Insulet's proactive approach to strengthening its overall financial performance.
Bears say
Insulet's 2026 operating income estimate has been revised downward to $549.3 million from $561.0 million, alongside a decrease in its EPS estimate from $6.09 to $5.74, indicating a weakening financial outlook. The anticipated introduction of competitive products poses a risk to Insulet's market position, as the company may struggle to establish itself effectively within the community before facing these headwinds. Additionally, the necessity for ongoing reductions in cost of goods sold (COGS) highlights concerns about the sustainability of Insulet's business model in the face of rising competition and potentially declining profitability.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares